严重特应性皮炎及相关瘙痒的临床表现、机制及最新治疗

IF 0.2 Q4 DERMATOLOGY
A. Kirchner, E. Lake
{"title":"严重特应性皮炎及相关瘙痒的临床表现、机制及最新治疗","authors":"A. Kirchner, E. Lake","doi":"10.1097/JDN.0000000000000661","DOIUrl":null,"url":null,"abstract":"ABSTRACT Atopic dermatitis (AD) is defined as a chronic inflammatory skin disease characterized by pruritus and xerosis. AD is the most common inflammatory skin disease, affecting about 200 million people worldwide. Although AD is diagnosed in all ages and races, there are distinct findings associated with the different age groups that can help guide the diagnosis. Recent, robust studies have identified hereditary and genetic risk factors, which have guided the treatment options for AD. This includes various topical agents, a new generation of systemic biologics (dupilumab, tralokinumab, and lebrikizumab), and Janus kinase inhibitors (abrocitinib and baricitinib). Here, we describe some of the common clinical manifestations, hypothesized mechanisms, and current therapeutic treatment options for patients with moderate-to-severe AD.","PeriodicalId":17315,"journal":{"name":"Journal of the Dermatology Nurses' Association","volume":"42 1","pages":"20 - 27"},"PeriodicalIF":0.2000,"publicationDate":"2021-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Manifestations, Proposed Mechanisms, and Updated Management of Severe Atopic Dermatitis and Associated Pruritus\",\"authors\":\"A. Kirchner, E. Lake\",\"doi\":\"10.1097/JDN.0000000000000661\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Atopic dermatitis (AD) is defined as a chronic inflammatory skin disease characterized by pruritus and xerosis. AD is the most common inflammatory skin disease, affecting about 200 million people worldwide. Although AD is diagnosed in all ages and races, there are distinct findings associated with the different age groups that can help guide the diagnosis. Recent, robust studies have identified hereditary and genetic risk factors, which have guided the treatment options for AD. This includes various topical agents, a new generation of systemic biologics (dupilumab, tralokinumab, and lebrikizumab), and Janus kinase inhibitors (abrocitinib and baricitinib). Here, we describe some of the common clinical manifestations, hypothesized mechanisms, and current therapeutic treatment options for patients with moderate-to-severe AD.\",\"PeriodicalId\":17315,\"journal\":{\"name\":\"Journal of the Dermatology Nurses' Association\",\"volume\":\"42 1\",\"pages\":\"20 - 27\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2021-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Dermatology Nurses' Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/JDN.0000000000000661\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Dermatology Nurses' Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JDN.0000000000000661","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

特应性皮炎(AD)是一种以瘙痒和干燥为特征的慢性炎症性皮肤病。AD是最常见的炎症性皮肤病,全球约有2亿人受到影响。尽管阿尔茨海默病可以在所有年龄和种族中诊断出来,但不同年龄组的不同发现可以帮助指导诊断。最近,强有力的研究已经确定了遗传和遗传风险因素,这指导了阿尔茨海默病的治疗选择。这包括各种局部药物,新一代系统生物制剂(dupilumab, tralokinumab和lebrikizumab)和Janus激酶抑制剂(abrocitinib和baricitinib)。在这里,我们描述了一些常见的临床表现,假设的机制,以及目前中重度AD患者的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical Manifestations, Proposed Mechanisms, and Updated Management of Severe Atopic Dermatitis and Associated Pruritus
ABSTRACT Atopic dermatitis (AD) is defined as a chronic inflammatory skin disease characterized by pruritus and xerosis. AD is the most common inflammatory skin disease, affecting about 200 million people worldwide. Although AD is diagnosed in all ages and races, there are distinct findings associated with the different age groups that can help guide the diagnosis. Recent, robust studies have identified hereditary and genetic risk factors, which have guided the treatment options for AD. This includes various topical agents, a new generation of systemic biologics (dupilumab, tralokinumab, and lebrikizumab), and Janus kinase inhibitors (abrocitinib and baricitinib). Here, we describe some of the common clinical manifestations, hypothesized mechanisms, and current therapeutic treatment options for patients with moderate-to-severe AD.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.30
自引率
25.00%
发文量
45
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信